INSIGHTS & POINT OF VIEW Sage Thoughts
News The latest from Sage
press releases
events
sage thoughts
HEALTHCARE PROVIDERS It’s an exciting time in neuroscience
At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to discover new pathways to brain health by making medicines that matter so patients can get better, sooner.
CLINICAL TRIALS A distinct approach to neuroscience drug development
Sage is committed to developing new medicines to treat life-altering brain health disorders.
PIPELINE Advancing a leading brain health portfolio
We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential brain health disorder treatments.Compound
Partners
Indications
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Marketed
Depression Franchise
ZULRESSO®
(brexanolone) CIV injection
(brexanolone) CIV injection
Postpartum Depression
100
Zuranolone
(SAGE-217)
(SAGE-217)
Major Depressive Disorder
80
Postpartum Depression
80
Treatment Resistant
50
Generalized Anxiety Disorder
50
Bipolar Depression
50
NEUROLOGY FRANCHISE
SAGE-324
Essential Tremor
40
Epileptiform Disorders
30
Parkinson's Disease
30
SAGE-689
Acute GABA Hypofunction
20
NEUROPSYCHIATRY FRANCHISE
SAGE-718
Huntington's Disease Cognitive Dysfunction
40
Parkinson's Disease Cognitive Dysfunction
40
Alzheimer's Disease Mild Cognitive Impairment and Mild Dementia
40
ADDITIONAL CLINICAL PROGRAMS
SAGE-319
GABA Hypofunction
20
SAGE-421
NMDA Hypofunction
10
CAREERS Rethinking brain health disorders to make life better for patients and their families
Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.
